BioNTech
BNTX
272 hedge funds and large institutions have $4.22B invested in BioNTech in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 92 increasing their positions, 74 reducing their positions, and 51 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 74
2.36% less ownership
Funds ownership: 21.27% → 18.91% (-2.4%)
4% less funds holding
Funds holding: 284 → 272 (-12)
7% less capital invested
Capital invested by funds: $4.56B → $4.22B (-$339M)
20% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 51
56% less call options, than puts
Call options by funds: $86.1M | Put options by funds: $198M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$141M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$68.9M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$54.8M |
| 4 |
BlackRock
New York
|
+$51.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$46.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$108M |
| 2 |
Jane Street
New York
|
-$105M |
| 3 |
Flossbach Von Storch
Cologne,
Germany
|
-$53M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$37.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$29.7M |
BNTX Hedge Fund Activity: Q1 2026 in Review
272 of the 8,186 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2026, worth a combined $4.22B — down 7.4% from $4.56B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of BNTX and 41 opened new positions — a net loss of 10 holders — while 74 trimmed existing stakes and 92 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $141M. The largest seller was Capital International Investors, exiting entirely with an estimated $108M sold.
- 272 institutional investors held BioNTech (BNTX) as of Q1 2026, down from 284 in Q4 2025.
- Funds reported $4.22B of BioNTech stock for Q1 2026, down 7.4% quarter-over-quarter.
- 41 funds opened new BioNTech positions in Q1 2026 and 51 closed out, a net change of -10 holders.
- The largest BioNTech buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $141M added.
- The largest BioNTech seller in Q1 2026 was Capital International Investors, an estimated $108M sold.
Based on aggregated 13F filings for Q1 2026.